ArticleJournal of biomedical science2014
Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems.
Article in Journal of biomedical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 61 citations in OpenAlex.
- Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.Journal of nanobiotechnology · 2026Review
- Chitosan nanoparticles for mucosal and needle-free vaccination.NPJ vaccines · 2026Review
- In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.ACS biomaterials science & engineering · 2025Review
- Current status and future directions for the development of human papillomavirus vaccines.Frontiers in immunology · 2024Review
- DNA vaccines as promising immuno-therapeutics against cancer: a new insight.Frontiers in immunology · 2024Review
- Chitosan non-particulate vaccine delivery systems.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: a review.Biotechnology letters · 2023Review
- NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice.BMC research notes · 2023Article
- Chitosan-Based Glycolipid Conjugated siRNA Delivery System for Improving Radiosensitivity of Laryngocarcinoma.Polymers · 2021Article
- Sustainable Agriculture Systems in Vegetable Production Using Chitin and Chitosan as Plant Biostimulants.Biomolecules · 2021Review
- Hybrid of niosomes and bio-synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment.Molecular biology reports · 2020Article
- Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies.Pharmaceutics · 2020Review
- CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.Cancer cell international · 2020Review
- Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice ModelIranian biomedical journal · 2019Article
- Hepatitis B virus S gene therapy with 10-23 DNAzyme delivered by chitosan-RSC advances · 2019Article
- Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Human gene therapy · 2018Article
- Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis.Molecular neurobiology · 2017Article
- Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2016Review
- Micro- and nanoparticulates for DNA vaccine delivery.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.Journal of biomedical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors. In this study, we have designed a therapeutic vaccine based on chitosan nanodelivery systems to deliver HPV-16 E7 DNA vaccine, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer. We have developed a Nano-chitosan (NCS) as a carrier system for intramuscular administration using a recombinant DNA vaccine expressing HPV-16 E7 (NCS-DNA E7 vaccine). NCS were characterized in vitro for their gene transfection ability.
resultsThe transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent proteins was well observed. In addition, NCS-DNA E7 vaccine induced the strongest E7-specific CD8+ T cell and interferon γ responses in C57BL/6 mice. Mice vaccinated with NCS-DNA E7 vaccine were able to generate potent protective and therapeutic antitumor effects against challenge with E7-expressing tumor cell line, TC-1.
conclusionsThe strong therapeutic effect induced by the Chitosan-based nanodelivery suggest that nanoparticles may be an efficient carrier to improve the immunogenicity of DNA vaccination upon intramuscular administration and the platform could be further exploited as a potential cancer vaccine candidate in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.